Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Mutation Causing Lesch-Nyhan Syndrome Linked to Other Neurological Disorders

By BiotechDaily International staff writers
Posted on 21 Oct 2013
Scientists have shown that gene expression errors impair the ability of stem cells to produce normal neurons, resulting instead in neurological disease. They indicate that at least some distinctly different neurodevelopmental and neurodegenerative disorders share basic, causative defects.

A gene mutation that causes a rare but destructive neurological disorder known as Lesch-Nyhan syndrome could help explain the developmental and neuronal defects found in other, diverse neurological disorders such as Alzheimer’s, Parkinson’s, and Huntington’s diseases. Lesch-Nyhan syndrome is caused by defects in the hypoxanthine guanine phosphoribosyltransferacgene (HPRT1), a gene that helps generate purine nucleotides, needed for DNA and RNA.

The findings, published in the October 9, 2013, issue of the journal PLOS ONE provide the first experimental picture of how gene expression errors impair the ability of stem cells to produce normal neurons, resulting instead in neurological disease. They indicate that at least some distinctly different neurodevelopmental and neurodegenerative disorders share basic, causative defects.

Mutations in the HPRT gene result in deficiencies in the HPRT enzyme, leading to defective expression of the neurotransmitter dopamine and subsequent abnormal neuron function. HPRT mutation is the specific cause of Lesch-Nyhan, an inherited neurodevelopmental disorder characterized by uncontrollable repetitive body movements, cognitive defects and compulsive self-mutilating behaviors.

They discovered that the cells do not develop normally. Instead, they differentiate from full-fledged neurons into cells that resemble and partially function as neurons, but also perform functions more typical of glial cells, a kind of supporting cell in the central nervous system. In addition, they noted that HPRT deficiency causes abnormal regulation of many cellular functions controlling important operational and reproduction mechanisms, DNA replication and repair and many metabolic processes.

The scientific team, headed by Theodore Friedmann, MD, professor of pediatrics at the University of California, San Diego School of Medicine (USA), says a gene mutation that causes a rare but destructive neurological disorder known as Lesch-Nyhan syndrome appears to explain the developmental and neuronal defects found in other, diverse neurological disorders like Alzheimer’s, Parkinson’s and Huntington’s diseases.

The scientists say that understanding defects in Lesch-Nyhan could help identify errant processes in other, more common neurological disorders, perhaps pointing the way to new kinds of therapies. Lesch-Nyhan syndrome is caused by defects in the hypoxanthine guanine phosphoribosyltransferacgene (HPRT1), a gene that is well-known for its essential tasks among them helping generate purine nucleotides–the building blocks of DNA and RNA.

“We believe that the neural aberrations of HPRT deficiency are the consequence of these combined, multisystem metabolic errors,” said Prof. Friedmann. “And since some of these aberrations are also found in other neurological disorders, we think they almost certainly play some role in causing the neurological abnormalities in diseases like Alzheimer’s, Parkinson’s, Huntington’s and possibly others. That makes them potential therapeutic targets for conditions that currently have limited or no treatments, let alone cures.”

Related Links:

University of California, San Diego School of Medicine



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.